TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Care Management on Diabetes Outcomes
Brief Summary: The purpose of the study is to determine if a nurse managed, protocol driven, disease management process for diabetes results in improved attainment of therapeutic goals for diabetes compared to usual care. It is hypothesized that implementation of the disease management process will improve the percentage of diabetic individuals attaining all three therapeutic targets (HgbA1C\<8.0%, LDL\<100mg/dl, and BP\<130/80mmHG) by 10% compared to usual care.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives
B: Arm Label: Telemedicine group; Type: EXPERIMENTAL; Interventions: Other: Telemedicine group | Arm Label: Conventional group; Type: PLACEBO_COMPARATOR; Interventions: Other: Conventional group | Intervention Type: OTHER; Name: Telemedicine group; Assigned to Arm(s): Telemedicine group | Intervention Type: OTHER; Name: Conventional group; Assigned to Arm(s): Conventional group
C: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Care Management on Diabetes Outcomes
Brief Summary: The purpose of the study is to determine if a nurse managed, protocol driven, disease management process for diabetes results in improved attainment of therapeutic goals for diabetes compared to usual care. It is hypothesized that implementation of the disease management process will improve the percentage of diabetic individuals attaining all three therapeutic targets (HgbA1C\<8.0%, LDL\<100mg/dl, and BP\<130/80mmHG) by 10% compared to usual care.


Options:
A: Arm Label: One-on-one counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Arm Label: Web counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle and medication intervention; Assigned to Arm(s): One-on-one counseling, Web counseling
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Framingham Risk Score; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Framingham and Genetic Risk Score; Type: ACTIVE_COMPARATOR; Interventions: Other: Genetic Risk Score | Intervention Type: OTHER; Name: Genetic Risk Score; Assigned to Arm(s): Framingham and Genetic Risk Score
D: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Care Management on Diabetes Outcomes
Brief Summary: The purpose of the study is to determine if a nurse managed, protocol driven, disease management process for diabetes results in improved attainment of therapeutic goals for diabetes compared to usual care. It is hypothesized that implementation of the disease management process will improve the percentage of diabetic individuals attaining all three therapeutic targets (HgbA1C\<8.0%, LDL\<100mg/dl, and BP\<130/80mmHG) by 10% compared to usual care.


Options:
A: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Physician/Pharmacist Collaborative Teams | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physician/Pharmacist Collaborative Teams; Assigned to Arm(s): Intervention
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Microvascular Coronary Disease In Women: Impact Of Ranolazine
Brief Summary: 1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity.
2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36).


Options:
A: Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): N/A
B: Arm Label: Study Drug Ranexa, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Arm Label: Placebo, Then Study Drug Ranexa(Ranolazine); Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo
C: Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study
Brief Summary: The overall objective of the study is to assess whether complete avoidance of cow's milk (CM) proteins, for at least the first 6 months of life, prevents type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a mother, biological father or sibling affected by type 1 diabetes.


Options:
A: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE
B: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula
C: Arm Label: A highly hydrolyzed casein formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: A highly hydrolyzed formula | Arm Label: A conventiona cow's milk based formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: A regular cow's milk based formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A highly hydrolyzed formula; Assigned to Arm(s): A highly hydrolyzed casein formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A regular cow's milk based formula; Assigned to Arm(s): A conventiona cow's milk based formula
D: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study
Brief Summary: The overall objective of the study is to assess whether complete avoidance of cow's milk (CM) proteins, for at least the first 6 months of life, prevents type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a mother, biological father or sibling affected by type 1 diabetes.


Options:
A: Arm Label: A highly hydrolyzed casein formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: A highly hydrolyzed formula | Arm Label: A conventiona cow's milk based formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: A regular cow's milk based formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A highly hydrolyzed formula; Assigned to Arm(s): A highly hydrolyzed casein formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A regular cow's milk based formula; Assigned to Arm(s): A conventiona cow's milk based formula
B: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study
Brief Summary: The overall objective of the study is to assess whether complete avoidance of cow's milk (CM) proteins, for at least the first 6 months of life, prevents type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a mother, biological father or sibling affected by type 1 diabetes.


Options:
A: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
B: Arm Label: A highly hydrolyzed casein formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: A highly hydrolyzed formula | Arm Label: A conventiona cow's milk based formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: A regular cow's milk based formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A highly hydrolyzed formula; Assigned to Arm(s): A highly hydrolyzed casein formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A regular cow's milk based formula; Assigned to Arm(s): A conventiona cow's milk based formula
C: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula
D: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug
Brief Summary: The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: OTHER; Interventions: Drug: Pregabalin | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: pregabalin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (unspecified) | Intervention Type: DRUG; Name: Comparator: pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): B
D: Arm Label: 1: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1: Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills
Brief Summary: The primary objective is to determine if continuous COC use leads to higher continuation rates over 12 months of follow up than use of the standard 28-day COC regimen.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: LNG-IUS (BAY 86-5028) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon) | Intervention Type: DRUG; Name: LNG-IUS (BAY 86-5028); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: 68 mg etonorgestrel implant for subdermal use (Nexplanon); Assigned to Arm(s): Arm 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel | Intervention Type: DRUG; Name: Oral contraceptives--ethinyl estradiol, levonorgestrel; Assigned to Arm(s): A, B
C: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring
D: Arm Label: Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300); Type: EXPERIMENTAL; Interventions: Drug: EE20/DRSP (BAY86-5300) | Arm Label: Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300); Type: EXPERIMENTAL; Interventions: Drug: EE20/DRSP (BAY86-5300) | Arm Label: Conventional regimen of EE20/DRSP (YAZ, BAY86-5300); Type: ACTIVE_COMPARATOR; Interventions: Drug: EE20/DRSP (YAZ, BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (BAY86-5300); Assigned to Arm(s): Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (BAY86-5300); Assigned to Arm(s): Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (YAZ, BAY86-5300); Assigned to Arm(s): Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)

Answer: B